Skip to content

LBRX LBRX Proceeds from issuance of preferred stock

Proceeds from issuance of preferred stock at other companies

MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
$49.71M

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+163%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock.

The official record: LBRX’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's proceeds from issuance of preferred stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's proceeds from issuance of preferred stock?
LBRX (LBRX) reported proceeds from issuance of preferred stock of $0 in Q4 2025.
How has LBRX's proceeds from issuance of preferred stock changed year-over-year?
LBRX's proceeds from issuance of preferred stock decreased by 100.0% year-over-year, from $10M to $0.
What does proceeds from issuance of preferred stock mean?
Cash received from issuing preferred stock — hybrid equity that provides fixed dividends without common stock dilution.